American journal of ophthalmology · 2026
Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Legala Akshara R, Nishida Takashi, Liang Ashley, Granet David, Burnett Lindsey A, Baxter Sally L, Rudell Jolene C
Аннотация
PURPOSE: To evaluate the association between menopausal hormone therapy (MHT) and strabismus outcomes in menopausal women.
DESIGN: Retrospective clinical cohort study.
PARTICIPANTS: Female patients in Epic Cosmos with a first menopause diagnosis between ages 44 and 60 years from January 1, 2010, to October 31, 2025 were included. MHT exposure was defined as estrogen or combined estrogen-progestin use for ≥90 days after menopause diagnosis; patients with prior MHT use were excluded.
METHODS: Demographic, clinical, and MHT data were extracted. Associations between MHT and strabismus diagnosis, surgery, and reoperation were assessed using time-varying Cox proportional hazards models adjusted for age and year of menopause diagnosis, race, and ethnicity.
MAIN OUTCOME MEASURES: Strabismus diagnosis, strabismus surgery, and reoperation, excluding congenital, mechanical, neurological, paralytic, and traumatic causes.
RESULTS: Among 2,154,255 menopausal patients, 197,576 (9.2%) received MHT and 1,956,679 (90.8%) did not. Mean age at menopause diagnosis was 54.9 (4.1) years, and 67.3% identified as White. MHT use was associated with higher hazards of strabismus diagnosis (HR 1.11, 95% CI 1.02-1.22; P = 0.015) and strabismus surgery (HR 1.76, 95% CI 1.38-2.25; P < 0.001), but not reoperation.
CONCLUSION: MHT was associated with increased risk of strabismus diagnosis and surgery in menopausal women, suggesting a potential relationship between MHT and ocular alignment outcomes.
DESIGN: Retrospective clinical cohort study.
PARTICIPANTS: Female patients in Epic Cosmos with a first menopause diagnosis between ages 44 and 60 years from January 1, 2010, to October 31, 2025 were included. MHT exposure was defined as estrogen or combined estrogen-progestin use for ≥90 days after menopause diagnosis; patients with prior MHT use were excluded.
METHODS: Demographic, clinical, and MHT data were extracted. Associations between MHT and strabismus diagnosis, surgery, and reoperation were assessed using time-varying Cox proportional hazards models adjusted for age and year of menopause diagnosis, race, and ethnicity.
MAIN OUTCOME MEASURES: Strabismus diagnosis, strabismus surgery, and reoperation, excluding congenital, mechanical, neurological, paralytic, and traumatic causes.
RESULTS: Among 2,154,255 menopausal patients, 197,576 (9.2%) received MHT and 1,956,679 (90.8%) did not. Mean age at menopause diagnosis was 54.9 (4.1) years, and 67.3% identified as White. MHT use was associated with higher hazards of strabismus diagnosis (HR 1.11, 95% CI 1.02-1.22; P = 0.015) and strabismus surgery (HR 1.76, 95% CI 1.38-2.25; P < 0.001), but not reoperation.
CONCLUSION: MHT was associated with increased risk of strabismus diagnosis and surgery in menopausal women, suggesting a potential relationship between MHT and ocular alignment outcomes.